MedTrace Logo

Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

NCT01116804 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-12-15

No results posted yet for this study

Summary

Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned.

The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).

Conditions

  • Primary Liver Cancer

Interventions

PROCEDURE

MRI of the liver before start of treatment

MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)

PROCEDURE

MRI after treatment

MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)

PROCEDURE

PET-scan before treatment start

PET-scan with 2 tracers is performed before treatment start

PROCEDURE

PET scan after treatment

PET-scan with 2 tracers is repeated 4 weeks following start of treatment

Sponsors & Collaborators

  • University Ghent

    collaborator OTHER

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Bieke Lambert, MD · University Hospital, Ghent

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-16
Primary Completion
2020-01-20
Completion
2020-01-20

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01116804 on ClinicalTrials.gov